Ian T. Mathews

Ian T. Mathews

Auto-generated profile, based on publicly available information

Ian T. Mathews

La Jolla Institute for Immunology, La Jolla, CA 92037, United States of America

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Molecular Cell
Verified
Journal Article
Closed access
RLRebecca K. Lau
Rebecca K. Lau
QYQiaozhen Ye
Qiaozhen Ye
EBErica A. Birkholz
Erica A. Birkholz
KBKyle R. Berg
Kyle R. Berg
LPLucas Patel
Lucas Patel
KCKevin D. Corbett
Kevin D. Corbett

1 February 2020 in Molecular Cell
Verified
Journal Article
Closed access
QYQiaozhen Ye
Qiaozhen Ye
RLRebecca K. Lau
Rebecca K. Lau
IMIan T. Mathews
Ian T. Mathews
EBErica A. Birkholz
Erica A. Birkholz
JWJeramie D. Watrous
Jeramie D. Watrous
KCKevin D. Corbett
Kevin D. Corbett

30 August 2023 in Nature
Verified
Journal Article
Closed access
PDF file
MRMiguel Reina-Campos
Miguel Reina-Campos
MHMaximilian Heeg
Maximilian Heeg
KKKelly Kennewick
Kelly Kennewick
IMIan T. Mathews
Ian T. Mathews
GGGiovanni Galletti
Giovanni Galletti
AGAnanda W. Goldrath
Ananda W. Goldrath

1 January 2013 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
SEShannon Patricia Fortin Ensign
Shannon Patricia Fortin Ensign
IMIan T. Mathews
Ian T. Mathews
MSMarc H. Symons
Marc H. Symons
MBMichael E. Berens
Michael E. Berens
NTNhan L. Tran
Nhan L. Tran
Glioblastoma (GB) is the most malignant of primary adult brain tumors, characterized by a highly locally-invasive cell population, as well as abundant proliferative cells, neoangiogenesis, and necrosis. Clinical intervention with chemotherapy or radiation may either promote or establish an environment for manifestation of invasive behavior. Understanding the molecular drivers of invasion in the context of glioma progression may be insightful in directing new treatments for patients with GB. Here, we review current knowledge on Rho family GTPases, their aberrant regulation in GB, and their effect on GB cell invasion and tumor progression. Rho GTPases are modulators of cell migration through effects on actin cytoskeleton rearrangement; in non-neoplastic tissue, expression and activation of Rho GTPases are normally under tight regulation. In GB, Rho GTPases are deregulated, often via hyperactivity or overexpression of their activators, Rho GEFs. Downstream effectors of Rho GTPases have been shown to promote invasiveness and, importantly, glioma cell survival. The study of aberrant Rho GTPase signaling in GB is thus an important investigation of cell invasion as well as treatment resistance and disease progression.

24 July 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
RDRekha Dhanwani
Rekha Dhanwani
MTMariko Takahashi
Mariko Takahashi
IMIan T. Mathews
Ian T. Mathews
CLCamille Lenzi
Camille Lenzi
ARArtem Romanov
Artem Romanov
SSSonia Sharma
Sonia Sharma
Metabolic analysis of ADA2-deficient cells shows that extracellular purine nucleosides trigger cellular innate immunity.

17 January 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
ARAlison Roos
Alison Roos
HDHarshil D. Dhruv
Harshil D. Dhruv
IMIan T. Mathews
Ian T. Mathews
LILandon J. Inge
Landon J. Inge
STSerdar Tuncali
Serdar Tuncali
Nhan L TranNhan L Tran
Nhan L Tran
Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells